Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05636436 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Immunogenicity of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 18 Years and Above

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date changed from estimate of Dec 30, 2024 to Sep 10, 2025 Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Dec 30, 2024 to May 23, 2025
    • Eligibility criteria expanded, about 21 words
    • Secondary endpoints: details revised at 6 of 25 entries
  2. 2 versions Re-verified since Mar 11, 2024, no change to tracked fieldsv4-v5
  3. Primary completion date: Dec 31, 2023 to Dec 30, 2024v3 Show 4 more changesShow less
    • Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Study completion date: Apr 30, 2024 to Dec 30, 2024
    • Start date changed from estimate of Dec 9, 2022 to Dec 7, 2022
    • Site contact updated
  4. Secondary endpoints: details revised at 1 of 25 entries
    • Study title revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purposes of the study are to evaluate the safety and tolerability of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 18 years and older, and to preliminarily explore immunogenicity.
Trial Details
NCT Number NCT05636436
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Collaborators: Henan Center for Disease Control and Prevention
Conditions
(from sponsor)		 Herpes Zoster
Related terms Herpes Zoster
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov